What's Happening?
Quiver Bioscience has received a multi-year grant from the National Institutes of Health (NIH) to advance its Nav1.7-targeted antisense oligonucleotide (ASO) therapy, QV-2421, through early clinical trials
for chronic neuropathic pain. The grant provides up to $9.3 million in direct funding and access to NIH-supported development resources. Chronic neuropathic pain affects 7-10% of the global population, and current therapies are effective in fewer than half of patients. Quiver's ASO-based approach targets Nav1.7, a sodium channel linked to pain transmission, aiming to deliver sustained pain relief without addiction risks.
Why It's Important?
The NIH grant supports the development of non-opioid therapies for chronic pain, addressing a significant unmet need in pain management. Quiver's approach could offer a safer alternative to opioid-based treatments, which carry risks of dependence and adverse effects. The research aligns with the NIH's HEAL Initiative, aimed at combating the opioid crisis and improving pain management. Success in this area could lead to new treatment options for millions of patients suffering from chronic pain, potentially reducing reliance on opioids.
